Non-Small-Cell Lung Cancer Metastatic
6
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
17%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC